Last $6.17 USD
Change Today +0.01 / 0.16%
Volume 3.2M
ARNA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

6154 Nancy Ridge Drive

San Diego, CA 92121

United States

Phone: 858-453-7200

Fax: 858-453-7210

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing drugs that target G protein-coupled receptors (GPCRs) to address unmet medical needs. In June 2012, the U.S. Food and Drug Administration (FDA) approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with a comorbidity or obese. The company is focused on commercializing BELVIQ in the United States and ultimately in additional territories, selectively advancing its drug candidates and discovering additional drug candidates. The company’s wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH) has provided Eisai Inc. (Eisai) exclusive rights to commercialize BELVIQ in the United States. The company also has granted exclusive marketing and distribution rights for BELVIQ to Eisai for most of the rest of North and South America and to Ildong Pharmaceutical Co., Ltd. (Ildong) for South Korea, subject to applicable regulatory approval in each of such territories. In 2012, the company submitted applications for the regulatory approval of BELVIQ in the European Union and Switzerland. The company’s proprietary GPCR-based technologies and its validated drug discovery and development approach are at the core of its research programs, enabling the company to internally discover and develop drug candidates. In addition to commercializing BELVIQ as a monotherapy for chronic weight management, the company intends to explore BELVIQ’s therapeutic potential in combination with other drugs and for other indications. The company’s research and development programs also include GPR119 and earlier-stage programs that span several therapeutic areas. Active Programs BELVIQ (lorcaserin HCl) In June 2012, the FDA approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with a comorbidity or obese. The DEA has proposed that BELVIQ be classified as a Schedule IV drug under the Controlled Substances Act, or CSA. Once the DEA finalizes the scheduling designation, BELVIQ would be available to eligible patients by prescription in the United States. The company has granted exclusive marketing and distribution rights for BELVIQ to Eisai for most of North and South America and to Ildong for South Korea. In addition, the company intends to enter into additional collaborations to support the commercialization of BELVIQ in other territories. BELVIQ Intellectual Property: As of February 15, 2013, the company owned issued patents that cover compositions of matter for the BELVIQ new chemical entity and related compounds and methods of treatment utilizing BELVIQ and related compounds in 69 jurisdictions, including the United States, Japan, Germany, France, China, Italy, Spain, Canada, the United Kingdom, Russia, Australia, India, and South Korea, and had applications pending in two other jurisdictions, of which the one with the largest pharmaceutical market was Brazil. As of February 15, 2013, the company owned registered trademarks on the use of the name BELVIQ in Class 5 for the sale and marketing of pharmaceutical preparations for weight management, weight loss, the treatment of obesity and the maintenance of weight loss in 61 jurisdictions, including the United States, Japan, Germany, France, China, Italy, Spain, the United Kingdom, Russia, Australia and South Korea, and had trademark applications pending in 80 other jurisdictions. As of February 15, 2013, the company also has filed trademark applications in Class 5 on one or more transliterations of the name BELVIQ in the local character set or alphabet of seven jurisdictions, including Japan, China, Russia and South Korea. APD811 Program APD811, an orally available agonist of the prostacyclin, or IP, receptor, is an internally discovered investigational drug candidate intended for the treatment of pulmonary arterial hypertension, or PAH. In October 2012, the company initiated a 28-day, multiple-dose, randomized, double-blind and placebo-controlled Phase 1 clinical trial in healthy volunteers to determine if dose escalation within patients could increas

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARNA:US $6.17 USD +0.01

ARNA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $7.45 USD -0.05
Array BioPharma Inc $4.09 USD +0.29
Rigel Pharmaceuticals Inc $3.19 USD -0.02
Spectrum Pharmaceuticals Inc $7.22 USD +0.04
Vivus Inc $5.08 USD -0.04
View Industry Companies
 

Industry Analysis

ARNA

Industry Average

Valuation ARNA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.5x
Price/Book 14.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARENA PHARMACEUTICALS INC, please visit www.arenapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.